Investigation of postjunctional α1- and α2-adrenoceptor subtypes in vas deferens from wild-type and α2A/D-adrenoceptor knockout mice

被引:19
作者
Cleary, L [1 ]
Vandeputte, C [1 ]
Docherty, JR [1 ]
机构
[1] Royal Coll Surgeons Ireland, Dept Physiol, Dublin 2, Ireland
关键词
rat vas deferens; alpha(1)-adrenoceptors; alpha(2A/D)-adrenoceptors; prazosin; BMY; 7378; BRL; 44408; RS; 100329;
D O I
10.1038/sj.bjp.0705137
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The subtypes of alpha(1)- and alpha(2)-adrenoceptor mediating contractions of vas deferens have been examined in wild-type and alpha(2A/D)-adrenoceptor knockout mice. 2 Maximum contractions to noradrenaline but not phenylephrine were significantly greater in vas from wild-type. The alpha(1A)-adrenoceptor antagonist RS100329 (5-methyl-3-[3-[4-[2-(2,2,2,-trifluoroethoxy)phenyl]-1-piperazinyl]propyll-2,4-(1H)-pyrimidinedione) (10 nm) significantly shifted the potency of noradrenaline. The alpha(2D)-adrenoceptor antagonist BRL 44408 (2-[4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole) significantly reduced the maximum contraction to noradrenaline in wild-type but not in knockout. 3 Following prazosin (0.1 muM), a component of the contraction to noradrenaline in wild-type but not in knockout was sensitive to the a2-adrenoceptor antagonist yohimbine. 4 Nifedipine (10 pm) or suramin (100 pm) reduced the contraction to 10 Hz stimulation for 4 s to an early peak and small maintained response. The peak was abolished by the alpha(1)-adrenoceptor antagonist prazosin. 5 RS100329 or prazosin inhibited 10Hz stimulation evoked contractions with a U-shaped concentration-response curve: inhibiting responses up to 0.1 mum, with a reversal of inhibition above this concentration. In the presence of suramin or nifedipine, the reversal of inhibition by high concentrations of prazosin was reduced. 6 The alpha(1D)-adrenoceptor selective antagonist BMY7378 (8-[2-(4-(2- methoxyphenyl)piperazin-1-yl)ethyl]-8-azaspiro[4,5]decane-7,9-dione) produced inhibition of 10 Hz evoked contractions only in high concentrations. 7 In conclusion, contractions to nerve stimulation in mouse vas deferens involve largely alpha(1D)-adrenoceptors and purmoceptors. alpha(1)-Adrenoceptor antagonists in high concentrations increase the purinergic response presumably by blocking prejunctional alpha(2)-adrenoceptor-mediated inhibition. In the presence of nifedipine, responses are predominantly alpha(1)-adrenoceptor mediated. Contractions to exogenous noradrenaline involved both alpha(1A)- and alpha(2A/D)-adrenoceptors in wild-type mice. British Journal of Pharmacology (2003) 138, 1069-1076. doi: 10. 1038/sj.bjp.705137.
引用
收藏
页码:1069 / 1076
页数:8
相关论文
共 29 条
[11]   BMY-7378 IS A SELECTIVE ANTAGONIST OF THE D-SUBTYPE OF ALPHA(1)-ADRENOCEPTORS [J].
GOETZ, AS ;
KING, HK ;
WARD, SDC ;
TRUE, TA ;
RIMELE, TJ ;
SAUSSY, DL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 272 (2-3) :R5-R6
[12]   ALPHA-1-ADRENOCEPTOR SUBTYPES LINKED TO DIFFERENT MECHANISMS FOR INCREASING INTRACELLULAR CA-2+ IN SMOOTH-MUSCLE [J].
HAN, C ;
ABEL, PW ;
MINNEMAN, KP .
NATURE, 1987, 329 (6137) :333-335
[13]   SUBCLASSIFICATION OF ALPHA-1-ADRENOCEPTOR RECOGNITION SITES BY URAPIDIL DERIVATIVES AND OTHER SELECTIVE ANTAGONISTS [J].
HANFT, G ;
GROSS, G .
BRITISH JOURNAL OF PHARMACOLOGY, 1989, 97 (03) :691-700
[14]   MOLECULAR CHARACTERIZATION OF ALPHA-1-ADRENOCEPTORS AND ALPHA-2-ADRENOCEPTORS [J].
HARRISON, JK ;
PEARSON, WR ;
LYNCH, KR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (02) :62-67
[15]   Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission [J].
Hein, L ;
Altman, JD ;
Kobilka, BK .
NATURE, 1999, 402 (6758) :181-184
[16]  
HIEBLE JP, 1995, PHARMACOL REV, V47, P267
[17]   Investigation of the subtypes of α2-adrenoceptor mediating prejunctional inhibition in rat atrium and cerebral cortex [J].
Ho, SL ;
Honner, V ;
Docherty, JR .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (06) :634-639
[18]   Investigation of the subtypes of α1-adrenoceptor mediating contractions of rat vas deferens [J].
Honner, V ;
Docherty, JR .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (06) :1323-1331
[20]  
Kava MS, 1998, BRIT J PHARMACOL, V123, P1359